Biotech Values

[mcbio]

It will be interesting to see how Squarer compares with Conway when it comes to partnering. Conway was pretty impressive IMO. When he said a partnership was coming he delivered. I remember before the Amgen partnership he said something along the lines of signing something within a matter of weeks and lo and behold he did. Hopefully Squarer is equally reliable.

Yes, agree completely regarding ARRY under Conway's leadership. When he talked, he generally did deliver. FWIW, Squarer comes off to me as more polished than Conway to me in the CCs. Obviously remains to be seen if he can live up to Conway's standards on partnerships and partnership terms.

I think the 2008 or 2009 10K was equally descriptive about 797 but for some reason they shelved the drug.

I really think it was to a large degree resource constraints given everything else ongoing. With some additional deals and additional funding, it allowed them more of a window to conduct additional trials with 797 I believe.

With all the question marks surrounding P38 inhibitors it may be a tall order to get a lucrative deal done so hopefully Squarer isn't setting up everyone for disappointment down the road. I think the focus should probably be on 614 and the MEK's and perhaps the GKA.

Yeah, I hear ya. Hopefully Squarer can deliver on a deal, and a good one at that. Keep in mind that it's by and large the partners driving the bus on the MEKs and AMGN is fully responsible for the GKA going forward. So, I certainly do expect ARRY to focus on 614 by and large with the possibility of 520 as well, though I'm not anywhere near as confident on the latter. Obviously ARRY doesn't expect to spend any more on 797 and hopes to find a partner.